Search

Reset

Status

Medical Condition

Displaying 1 - 3 of 3

Study For Previously Treated Patients Of Light-Chain Amyloidosis Using Study Drug Carfilzomib

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Read More

Multiple Sclerosis (MS) Patient Response to COVID-19 Outbreak: Recruiting Participants with and without MS

Condition: COVID-19 (Coronavirus)
Investigator: Philip De Jager, PhD
Status: Closed
We need your help today to gather information about the experience of multiple sclerosis (MS) patients and the general population during the COVID-19 pandemic. Most MS patients take one of over a dozen of medications to control their disease, and these medications alter the immune system. These effects are not as strong as those experienced by patients with…
Read More

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Read More